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Abstract: Myocarditis is a challenging and potentially life-threatening disease associated with high
morbidity in some paediatric patients, due to its ability to present as an acute and fulminant disease
and to ultimately progress to dilated cardiomyopathy. It has been described as an inflammatory
disease of the myocardium caused by diverse aetiologies. Viral infection is the most frequent cause of
myocarditis in developed countries, but bacterial and protozoal infections or drug hypersensitivity
may also be causative agents. The prompt diagnosis in paediatric patients is difficult, as the spectrum
of clinical manifestation can range from no myocardial dysfunction to sudden cardiac death. Recent
studies on myocarditis pathogenesis have revealed a triphasic nature of this disease, which influences
the diagnostic and therapeutic strategies to adopt in each patient. Endomyocardial biopsy remains
the gold standard for diagnosing myocarditis, and several non-invasive diagnostic tools can be used
to support the diagnosis. Intravenous immunoglobulin has become part of routine practice in the
treatment of myocarditis in paediatric patients at many centres, but its true effect on the cardiac
function has been the target of many studies. The aim of this review is to approach the recently
discovered facets of paediatric myocarditis regarding its progression to dilated cardiomyopathy.
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1. Introduction
Myocarditis is a non-familial form of inflammatory heart muscle disease, in the absence of
predominant acute or chronic ischaemia [1–3]. It is, by definition, an inflammation of the myocardium,
which may also extend to the pericardium and endocardium [4]. Diagnosis is established by histological,
immunologic and immunohistochemical criteria, as it was defined by the World Health Organization
(WHO)/International Society and Federation of Cardiology (ISFC), in 1995 [5]. It is an important cause
of morbidity and mortality in children, due to its association with cardiac dysfunction and dilated
cardiomyopathy (DCM), which may represent the chronic phase of the disease [5,6].
2. Aetiology
Acute myocarditis has multiple causes, including viruses, protozoa, bacteria, fungi, toxins, drugs,
metabolic abnormalities, hypersensitivity reactions and systemic autoimmune diseases [7]. Often the
underlying agent causing the disease is not identified [4].
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2.1. Infections
More than 50% of paediatric acute myocarditises in Western Europe and North America are
caused by cardiotropic viruses [8,9]. The pattern of viral pathogens associated with myocarditis has
evolved over the last 20 years [10]. Enteroviruses (particularly coxsackieviruses) have traditionally
been considered the most frequent viral agents in myocarditis and DCM [11,12]. More recently,
new molecular techniques have revealed that the most commonly detected viral agents were
Parvovirus B19 and human herpesvirus type 6 [12–14]. Other previously unrecognized viruses
associated with myocarditis with varying degrees of frequency include adenovirus, cytomegalovirus,
Epstein–Barr, hepatitis C, herpes simplex type 2, influenza and parainfluenza viruses [9,11,13,15–19].
In 2010, Bratincsák et al. reported three cases of fulminant myocarditis in a paediatric population
associated with the pandemic H1N1 influenza A virus infection, and it is hypothesized that this
strain may be more associated with severe forms of myocarditis than other influenza strains [20].
Human immunodeficiency virus (HIV) has also been associated with myocarditis, which is often
asymptomatic [21]. HIV myocarditis may cause both systolic and diastolic dysfunction in paediatric
patients [22]. Some agents are thought to be responsible for the initiation of these processes and the
presence of viral nucleic acid in the myocardium, a common finding in HIV+ children, may be one of
them [23]. Infection of myocytes with other agents, like fungi, parasites or other viruses other than HIV
may be associated with the development of DCM and congestive heart failure [23,24]. Some drugs
used in highly active antiretroviral therapy (HAART) regimens, like Zidovudine, are cardiotoxic
themselves [22].
Bacteria and other infectious causes, such as protozoa, fungi, and parasites, have been known to
cause myocarditis far less commonly than viruses [25]. Toxin-producing bacteria, including Clostridium
and Diphtheria, can cause severe myocardial damage, the latter causing myocarditis in countries
without widespread immunization [21,26]. Lyme disease, caused by the spirochete Borrelia burgdorferi,
can also result in acute myocarditis [7]. However, it is considered the least common manifestation
of early disseminated Lyme borreliosis in children and progression to DCM is rare [7,27]. In 2009,
Costello et al. reviewed 207 cases of children with early disseminated Lyme disease and found
that 16% had myocarditis, 42% of whom had advanced atrioventricular heart block, including 27%
with third-degree heart block [28]. In Latin-American countries, Chagas disease, which results from
an infection due to the protozoan Trypanosoma cruzi, is a common cause of acute myocarditis and
DCM [10,29]. In recent years, as a consequence of effective control of the transmission of the protozoan,
acute Chagas myocarditis has reduced in Brazil [7].
2.2. Hypersensitivity to Drugs and Other Substances
Drugs may also cause myocardial inflammation via a direct cardiotoxic effect or by inducing
hypersensitivity reactions [4]. Hypersensitivity myocarditis is a rare form of inflammatory disease
of the myocardium [30]. The molecular basis is poorly understood, but it is thought to be a
hypersensitivity reaction to haptens from the cardiotoxic drug [31]. This diagnosis should always be
suspected when clinical presentation occurs in a setting consistent with drug allergy because of its
excellent prognosis after withdrawal of the causative toxin [32]. Some agents have been reported to
be implicated in hypersensitivity myocarditis in paediatric patients. These include chemotherapeutic
drugs, such as anthracyclines, dermatology drugs, like dapsone, and also tetanus and smallpox
vaccines [30,33–35].
These drug-induced hypersensitivity responses are often associated with an eosinophilic
myocarditis, which is usually revealed after an endomyocardial biopsy (EMB) [21]. In this situation,
withdrawal of the offending medication may not always be enough and corticosteroid therapy may be
needed [36].
3. Myocarditis: A Triphasic Disease Process
Since the majority of cases of myocarditis result from a viral infection, it has long been studied
in experimental murine models as a virus-induced autoimmune disease, which may progress to
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gradual myocardial dilatation [3,37]. Myocarditis progresses through stages with distinct processes and
manifestations. Thus, it has been helpful to set it in the structure of a continuum of three chronologically
successive phases of disease (Figure 1). For each phase, pathogenesis, diagnosis, and treatment differ
significantly [37,38].
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The three-phased course starts wi the first phase, which is an i duction stag where the virus
plays a major role in the initial insult to the myocardium [6,38]. The entry and active replication of
the virus is followed by cardiomyocyte lysis and activation of the host innate immune responses.
In most patients, the immune system downregulates to a resting state after viral proliferation is brought
under control and they recover without significant sequelae [3,37]. Thus, the initial insult often goes
unnoticed [38].
If host immune activation persists despite elimination of the virus, the second phase develops as
a result of both adaptive immune and autoimmune responses [38]. The activation of antigen-specific
immunity involving T cells, B cells and antibody production contributes to additional myocardial
injury with deleterious effects [3,10]. Development of autoantibodies can be induced by molecular
mimicry between myocardial antigens and viral peptides [10,38]. Clinically overt congestive heart
failure may develop in this phase [38]. In the majority of patients, the virus is eliminated and the
immune reaction is downregulated [3].
However, a subset of patients progresses to a third phase in which the inflammatory processes
persist and the disease develops into DCM and it may progress despite the ending of the first
phases [3,38]. Viral myocarditis has become recognized as an important cause of DCM in children.
Miranda et al. performed a retrospective review of 61 paediatric patients (37 female; 24 male) diagnosed
with DCM and found that viral myocarditis was the aetiology in 18% of cases [39].
4. Pathogenic Mechanisms
The causal connection between myocarditis and its progression to DCM and heart failure is not
completely understood but has been hypothesized for many years [40]. Different studies using murine
models of myocarditis have contributed to what is currently known about the pathogenesis of the
disease [4]. Viral mediated cardiomyocyte injury, autoimmunity and persistent viral infection are three
theories assumed to explain this process [41].
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The disease begins with viral entry into cardiomyocytes [21]. Specific receptors have been
identified on human myocytes, such as the Coxsackie-adenoviral receptor (CAR) for Coxsackieviruses
of group B and some adenoviruses, and the erythrocyte P-antigen cellular receptor for Parvovirus
B19 [42–46]. Replicating viruses in the absence of an immune response causes myocytolysis, which
is the primary lesion responsible for focal necrosis and inflammation of the myocardium [40,47].
Subsequently, innate and adaptive immune responses are activated [7,38]. Many host pro-inflammatory
mediators are upregulated in an attempt to limit viral replication, including cytokines such as tumour
necrosis factor-α (TNF-α), interleukin (IL)-1 and IL-6, nitric oxide, macrophages and natural killer
(NK) cells [21,48]. Additionally, T lymphocyte (CD4+ and CD8+) activation was described to induce
cytokine production as well as apoptosis of targeted cells mediated by perforins, serine esterases and
the Fas ligand/Fas receptor pathway [49]. Even though these mechanisms are an essential path to
recovery, their cumulative effect is harmful since they also enhance myocardial tissue injury, therefore
contributing to the loss of virus-harbouring myocytes [21,38,50]. The decrease in the number of
contractile units and their inability to regenerate may lead to long-term remodelling and a clinical
picture consistent with DCM [6,7].
Autoimmunity has also been recognized as having an important role in the progression of viral
myocarditis [41]. Secondarily to myocyte necrosis comes the exposure of heart muscle antigens [51].
Questions remain whether this mechanism is the only one triggering the autoimmune disease or if
molecular mimicry may also play a part [41]. When activated B lymphocytes produce antibodies that
cross-react with these antigens the autoimmune response begins and viral myocarditis progresses [7,41].
Anti-sarcolemmal, anti-myosin alpha and beta heavy chains, anti-mitochondrial proteins, and anti-β1
adrenergic receptor antibodies have all been identified in patients with DCM [7,52].
According to Kuhl et al., persistent viral genome can be found in 67.4% of adult patients with
DCM, which is most likely caused by incomplete clearance of the pathogen [4,53]. The exact role of a
persistent cardiac infection in the development of DCM in paediatric patients has not been defined
yet [38]. It is hypothesized that continuous or intermittent virus replication may result in a chronic
myocyte damage and autoimmune injury [21,41].
5. Clinical Presentation
Clinical manifestation of the disease in children has a variable spectrum, ranging from non-specific
systemic symptoms with no haemodynamic consequences (fever, myalgia, palpitations or dyspnoea)
to congestive heart failure, ventricular dysfunction, shock and life-threatening ventricular arrhythmias,
which consequently can lead to sudden cardiac death [6,7,54]. Syncope and chest pain may also
be presenting complaints [10]. The latter can mimic adult myocardial infarction with anterior chest
pressure pain radiating to the neck and arms and is typically seen in younger patients with few
cardiac risk factors [2,4,55]. This acute myocardial infarction-like syndrome can be associated with
electrocardiographic changes, such as ST segment elevation, and elevated biomarkers of myocardial
cell damage (creatine kinase and/or troponin I), in a context of normal coronary arteriography [2,7,56].
Many patients may present with mild unspecific prodromal symptoms typical of a viral illness,
such as shortness of breath, vomiting, anorexia, abdominal pain, diarrhoea, fever, myalgia, lethargy,
syncope or seizures [4,7,57,58]. A history of respiratory tract infection or gastroenteritis may precede
the onset of myocarditis by several days to a few weeks [7]. In 2009, Durani et al. performed a
retrospective review of the presenting symptoms in patients ultimately diagnosed with myocarditis,
and the most frequently described were shortness of breath (69%), vomiting (48%), poor feeding (40%),
upper respiratory symptoms (39%), fever (36%), and lethargy (36%) [59].
Clinical features also vary according to age. Infants may present with nonspecific symptoms
like anxiousness, malaise, fever, poor appetite, tachypnoea, tachycardia, and cyanosis [21]. Children
greater than two years of age may also complain of chest pain, shortness of breath, abdominal pain,
exercise intolerance, myalgia, arthralgia, fatigue, palpitations, cough or oedema [21,41,60].
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The severity of symptoms is dependent on the age of the child [21]. Newborns and infants are
often more severely affected and, in contrast to older children and adults, they are more likely to
present with circulatory shock and acute DCM and may require advanced circulatory and respiratory
support in early stages of their disease [61,62].
6. Differential Diagnoses
Since myocarditis symptoms are not specific, other diseases can present in a similar clinical
pattern [6,63]. In the newborn or infant, sepsis, hypoxia, severe dehydration, hypoglycaemia or
anaemia must be ruled out. Other diagnoses should also be excluded, such as endocarditis and
endocardial fibroelastosis. Genetic X-linked disorders, like Barth syndrome, as well as congenital
structural heart lesions, such as critical coarctation of the aorta or anomalous origin of the left coronary
artery from the pulmonary artery or even a cerebral arteriovenous malformation may also be present.
In the older child, chronic tachyarrhythmia and pericarditis are two other differential diagnosed
conditions to add to the previously listed.
As far as DCM is concerned, only one-third of the patients enrolled in a Paediatric
Cardiomyopathy Registry study had a known cause of DCM at diagnosis [64]. On the subject
of differential diagnoses, it is very important to consider familial DCM, since it comprises 14%
of all paediatric DCM cases with a known cause and it carries a worse prognosis than other
aetiologies [65–67]. Many mutations with autosomal dominant, recessive, X-linked, and mitochondrial
inheritance patterns associated with the DCM phenotype have been identified [68]. Family cardiac
screening may carry some advantages if done quickly, particularly the possibility of avoiding the need
for the performance of other invasive and expensive diagnostic tools [65]. Other alternate diagnoses
consistent with clinical presentation of symptomatic heart failure should be excluded, such as metabolic
DCM (comprising 11% of paediatric DCM cases with a known cause), valvular and congenital heart
disease (occurring in only 3% of paediatric DCM cases with a known aetiology), bronchiolitis, thyroid
disease and chemotherapy-related cardiomyopathy [66,69–71]. Some genetic disorders, involving 26%
of paediatric DCM cases with a known cause, like Emery–Dreifuss muscular dystrophy, Laing distal
myopathy or Duchenne and Becker muscular dystrophy should be investigated in idiopathic DCM,
after exclusion of all other identifiable causes [66,70].
7. Diagnosis and Treatment: A Triphasic Approach
Having in mind the triphasic framework of myocarditis, it is helpful to systematize its diagnostic
and therapeutic strategies, which are considerably different for each stage of disease [38].
7.1. First phase: Viral Replication
7.1.1. Diagnosis
Initially, the diagnosis of myocarditis is very dependent on clinical suspicion based on history
and clinical picture of the disease, especially when cardiac involvement is apparent [6,7]. However,
the wide range of clinical manifestations of paediatric myocarditis may easily transpire unnoticed by
the clinician [59].
Definite diagnosis of viral myocarditis can only be proved by finding evidence of active viral
infection, using histological or serological identification of virus [6,38]. EMB used to be required to
define myocarditis according to the Dallas criteria [4]. Since it is not performed routinely in some
centres, there are several non-invasive tests that can support the suspected diagnosis, something that
is particularly important in paediatric patients [72].
The 12-lead electrocardiogram (ECG) is an easily available initial test [4]. Retrospective studies
have found abnormal ECGs in 93% to 100% of paediatric patients with myocarditis [59,73]. However, a
normal ECG does not exclude the possibility of the disease [57]. The most common findings in the acute
phase of clinical myocarditis are sinus tachycardia with low-voltage QRS complexes and nonspecific
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T-wave changes, but these are not specific markers [4,6,21]. The ECG may also reveal ST-segment
decrease or elevation, occasionally resembling a pattern seen in acute myocardial infarction [74,75].
Although commonly used as a screening tool, an ECG has the sensitivity of only 47% for the diagnosis
of myocarditis in paediatric patients [76,77].
Echocardiography is still the most useful imaging technique to be performed in paediatric
suspected cases to assess left ventricular structure, wall motion abnormalities, regional or global
ventricular dysfunction and valvular insufficiency, since these abnormalities are often present in
acute myocardial inflammation [7,10,78]. However, there are no specific echocardiographic features
of myocarditis and they are usually insufficient to differentiate this disease from other forms of
cardiomyopathy [6,51].
Cardiac MRI (cMRI) is proving to be the most attractive imaging tool for diagnosing myocardial
inflammation and myocyte injury, especially if performed within 14 days of the beginning of
symptoms, when the sensitivity for the diagnosis is higher (Figure 2) [6,79]. In addition to its
unique potential for providing anatomic and morphologic information, cMRI has the ability
to characterize tissue by measuring T1 and T2 relaxation times and spin densities, which are
dependent on water content [80,81]. Detection of myocardial oedema, the initial change in myocardial
tissue during the first phase of inflammation, is measured with T2-weighted imaging [51,80].
Gadolinium diethylenetriaminepentacetate (Gd-DTPA) is used as an extracellular contrast agent
in contrast-enhanced cMRIs, and it distributes differently according to the type of cardiac tissue,
inflamed or normal tissue [7]. Early enhancement in T1-weighted images obtained minutes after
Gd-DTPA infusion may assess hyperaemia, but it is not the most specific finding for the diagnosis
due to artefacts [82,83]. On the other hand, delayed Gd-DTPA enhancement suggests the presence
of myocardial fibrosis and necrosis associated with myocarditis, lesions that are often histologically
patchy in nature [7,84]. One cMRI approach to diagnose myocarditis is the Lake Louise criteria
(LLC) [85]. The diagnosis is made if two out of three LLC criteria are met: (i) increased myocardial
early Gd-DTPA enhancement ratio or absolute myocardial enhancement of ≥45% on T1-wheighted
images; (ii) increased myocardial signal intensity on T2-weighted images (increased T2-ratio or
regional increase in T2 signal intensity); and (iii) non-ischaemic lesions at late Gd-DTPA enhancement
imaging [83]. Even though the LLC have shown some utility, particularly in patients with acute onset
of symptoms, their qualitative nature and bad performance when applied in patients with heart
failure and chronic symptoms has contributed to the search for novel quantitative T1 and T2 mapping
techniques, including the quantification of extracellular volume [85]. A recent study performed in
adult patients showed that myocardial T1 and T2 mapping and T1-derived extracellular volume
fraction significantly improved the diagnostic accuracy of cMRI compared with conventional LLC [86].
By identifying areas of myocardial inflammation globally, cMRI offers an advantage in the diagnosis
of this disease when compared to EMB and may even be used to direct it, consequently improving
its diagnostic sensitivity [6,87]. However, cMRI with delayed Gd-DTPA enhancement alone has been
reported to have a relatively low sensitivity in visualizing areas of myocarditis in adult patients,
ranging from 27% to 95% [75]. Additionally, the use of cMRI in routine practice is limited by the lack
of availability in most emergency settings and the need for general anaesthesia in young paediatric
patients [88].
EMB is still the gold standard of diagnosing acute myocarditis even though in the past its
routine clinical use for the diagnosis of myocarditis was not recommended [7,10]. The 2013 position
statement of the European Society of Cardiology Working Group recommended that all patients with
clinically suspected myocarditis should be considered for selective coronary angiography and EMB [89].
The role of EMB is undeniable, since immunohistochemistry and immunofluorescence techniques,
viral DNA or RNA identification by PCR and real-time PCR amplification of viral genome, used in
conjunction with standard EMB, provide an increase in diagnostic sensitivity [6,89]. However, EMB is
not routinely performed to diagnose myocarditis [90]. The sensitivity of this diagnostic tool is limited
due to sampling error and the rate of major complications associated with this procedure is variable,
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ranging from <1%, when performed in experienced centres, to 5% [91–93]. Some of the adverse
events associated with EMB in paediatric patients may include atrial tachyarrhythmia, transient
hypotension attributed to anaesthesia, transient ST-T wave changes, supraventricular tachycardia
requiring electrical cardioversion, ventricular fibrillation and myocardial perforation [94].
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Figure 2. A 15-year-old boy with Epstein–Barr virus myocarditis: (a) a short-axis T2-weighted image
demonstrating focal myocardial oedema (red arrows); and (b) a short-axis T1-weighted late gadolinium
enhancement image (red arrows). RV, right ventricle; LV, left ventricle.
7.1.2. Treatment
Management of an early fulminant disease with cardiogenic shock is fundamentally supportive
and is not aimed at the causative agent [7]. Paediatric patients with severe haemodynamic compromise
related to myocarditis require rescue with aggressive support measures, including inotropic therapy
and arrhythmia management, which may be life-saving [95]. Mechanical circulatory support devices
such as ventricular assist devices (VADs) and extracorporeal membrane oxygenator (ECMO) should
be considered early in patients who have severely compromised cardiac output despite optimal
pharmacological treatment [4,96–99].
In initially stable patients or in the ones who survive the initial critical phase, therapy in the first
stage of myocarditis may benefit from pharmacological eradication of the responsible viral agent in
order to attenuate the cardiac injury [38]. However, direct antiviral therapies are only helpful in the
small amount of cases in which the viral pathogen has established itself—like ganciclovir for CMV
infection—or in the setting of a viral epidemic [6,100]. In this phase, it is extremely important to avoid
both potentially damaging immunosuppression and non-specific antiviral procedures [6].
7.2. Second Phase: Autoimmune Activation
7.2.1. Diagnosis
The autoimmune stage is diagnosed by EMB, which may show lymphocytic infiltration [6,38]. The
original description of the histology of inflammation of the myocardium in patients with myocarditis
was stated in the qualitative Dallas criteria as the presence of lymphocytic infiltrates in the myocardium
associated with myocyte necrosis of non-ischaemic cause [4,101]. More recently, immunohistochemistry
techniques have gained further acceptance in the detection of inflammation in EMBs, contributing
to the increased number of EMB revealing myocarditis [5,10,102]. During EMB analysis, specific
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inflammatory cells can be distinguished by cluster differentiation (CD) [101]. Monoclonal antibodies
to CD3 and CD68 or CD11 allow the detection and localization of T cells and activated macrophages,
respectively [10]. CD20 stands for B-cells [101]. Human leukocyte antigen (HLA) can be used to
detect HLA class II expression in professional antigen-presenting immune cells [10,37]. The addition
of immunohistochemical criteria in the analysis of EMBs has made it possible to quantitatively define
myocardial inflammation as focal and diffuse mononuclear infiltrates with >14 leucocytes/mm2 [5,101].
T cell subpopulations may include CD4 (helper), CD8 (suppressor) and CD45R0 (memory or activated
T-cells) [101]. Having these subpopulations in mind, inflammation may be more specifically diagnosed
by >7.0 CD3+ lymphocytes/mm2 and/or >35.0 CD11b+/Mac-1+ macrophages/mm2 [103].
Viral serologies may be abnormal as well [6]. However, IgG antibodies for cardiotropic viruses
are often positive in the blood stream without associated cardiac involvement, a fact that limits its
significance in the diagnostic process [6,104].
7.2.2. Treatment
Since autoimmunity myocardial inflammatory processes may take place despite virus elimination,
immunomodulatory therapies targeting the host immune system can be efficacious [4,7]. However,
this topic remains controversial in the paediatric age group due to the reduced number of studies
performed and the lack of respective controls [7]. Some administered immunomodulatory strategies
include immunosuppression with corticosteroids, intravenous immunoglobulin (IVIG), azathioprine,
and cyclosporine [105].
Corticosteroid treatment remains controversial when it comes to its benefit in children with
myocarditis [106]. While some recent studies have shown improvement in left ventricular ejection fraction
(LVEF) and symptoms among children treated with corticosteroids and/or other immunosuppressive
agents, like cyclosporine, others found no differences in the final outcome [16,107–109]. The only
aspect that seems to be commonly accepted is that immunosuppression with corticosteroids should
not be used in the acute phase of myocarditis since it interferes with its natural eradication and,
therefore, prolongs the disease [109].
IVIG has become part of routine immunomodulatory therapy for treating children with acute
myocarditis at many centres, in a standard high-dose of 2 g/kg per 24 h [4,110]. There is a possibility
that paediatric patients are more likely to respond to IVIG than adults due to a higher chance of a viral
myocarditis [110]. Drucker et al. performed a retrospective study to assess the effect of a 2 mg/kg
dose of IVIG therapy in 21 consecutive children with presumed acute myocarditis on survival and
recovery of left ventricular function [111]. Their experience found that the use of high-dose IVIG was
associated with improvements in recovery of left ventricular systolic function and a tendency toward
better overall survival during the first year after presentation [10,111]. Nigro et al. reported a case of
a seven-month-old girl with a severe myocarditis and persistent Parvovirus B19 DNA in the blood,
who received IVIG therapy containing neutralizing antibodies specific to that virus [112]. The clinical
improvement and viral clearing suggested the beneficial role of this therapeutic agent. A paediatric
trial conducted by Bhatt et al. in India evaluated the efficacy of IVIG among 83 children (ages ranging
from two months to 12 years) with suspected viral encephalitis and associated myocarditis [113].
They found a lower death rate among children receiving IVIG than in those who did not, and it is
suggested that IVIG may be useful in the select group of children beyond the neonatal period who
have the association of both viral diseases. Thus, a high risk of bias is present in this study, since
it is not clear whether this benefit extends to children with myocarditis alone [110]. On the other
hand, a retrospective analysis revealed that the treatment with IVIG provided no advantage in overall
survival and time to recovery of normal left ventricular function in comparison to steroid therapy
alone [114,115]. The question of IVIG role in paediatric myocarditis remains to be answered [114].
The insufficient evidence to support its routine use may require a prospective randomized study in
order to truly assess the advantage of this treatment in this specific population [6,10,110].
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Immunoadsorption is a therapeutic concept currently under discussion [6]. Its aim is to eliminate
cardiotoxic autoantibodies together with cytokines, which have been associated with DCM [116,117].
Repetitive plasmapheresis sessions allow the removal of IgG primarily and little amount of IgA and
IgM, and have been associated with improvement in cardiac function and reduction of oxidative
stress [118–120]. In some studies, polyclonal IgG has been given at the end of the procedure, in order to
provide an additional immunomodulatory effect [6]. The exact mechanism of action is still not known,
but the benefit of this process may come from the removal of circulating autoantibodies, elimination of
cytokines or unloading of the heart and the circulation by the temporary removal of proteins [119,121].
Jahns et al. have provided direct evidence of specific circulating β1-adrenoceptor
antibodies [122,123]. This autoimmune attack, which also plays a causal role in DCM, can be eradicated
with the elimination of the β-receptor antibody [6]. However, this pathophysiologically appealing
concept lacks randomized clinical trials [6,119].
7.3. Third Phase: Dilated Cardiomyopathy
7.3.1. Diagnosis
This phase is identified by the usual imaging tools in order to exclude other causes of dilatation
(Figures 3 and 4) [6]. When it comes to echocardiography, it is important to acknowledge that even
though the most frequent echocardiographic finding associated with myocarditis is a DCM phenotype
of left ventricular dilatation and reduced ejection fraction, other parameters of ventricular remodelling
may be present in histologically proven myocarditis, including regional hypertrophy and regional
wall motion abnormalities [7,124]. The left ventricle of a patient with acute myocarditis may even lack
significant dilatation [4].
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7.3.2. Treatment
Therapy after absence of both infectious and autoimmune stages is focused on prevention and
reversal of the unfavourable remodelling process of the myocardium and reduction of haemodynamic
stress by using angiotensin converting enzyme (ACE) inhibitors, β-blockers and spironolactone [6,37,38].
β-blockers like carvedilol can be cautiously introduced only in stable patients and the dose should be
titrated slowly [125]. These agents must be stopped whenever inotropes are needed [121].
Anticoagulation with warfarin in DCM stage is difficult in young infants and many clinicians
prefer to use aspirin in patients with severely compromised cardiac output or atrial dysrhythmias, in
order to prevent the formation of mural thrombi [126,127]. However, aspirin and other non-steroidal
anti-inflammatory agents have been associated with exacerbation of heart failure, probably due to the
inhibition of prostaglandin synthesis, which ultimately may lead to a decrease in renal perfusion [121].
Their use is not recommended in adult patients with reduced left ventricular function according to
the “2016 European Society of Cardiology Guidelines for the diagnosis and treatment of acute and
chronic heart failure” [128]. Prophylactic aspirin should be reserved for paediatric patients with DCM
who have not experienced any previous thromboembolic event or intracardiac thrombus, with LVEF
between 25% and 30% or fractional shortening (FS) between 15% and 20%. Treatment should be
stopped whenever systolic function improves [129].
Although paediatric myocarditis often improves within the first months of presentation, a minority
of patients may progress to severe heart failure, which is unresponsive to optimal medical therapy,
therefore requiring cardiac transplantation [7,10,21].
These patients need to be frequently monitored throughout their lives and a complete history,
examination, and echocardiography should be undertaken [37].
8. Prognosis
Since a significant number of cases of myocarditis do not get diagnosed due to the unspecific
symptoms, its true incidence and outcome remain difficult to characterize [7,61,97,130]. A lack
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of studies aiming to assess the prognosis of paediatric myocarditis adds to the difficulty and the
extrapolation of outcomes from the adult to the paediatric population should not be assumed [97].
The main outcomes paediatric patients can experience include complete recovery, progression
to DCM and death or transplantation [4,61,91]. According to Peta and co-workers’ 20-year study of
175 children with myocarditis, survival free from death or transplantation was 74% at one year, 65% at
five years, 62% at 10 years, and 56% at 20 years. At 15 years after diagnosis, 60% of the participants
remained free from transplantation, of whom 69% achieved echocardiographic normalization of
left ventricular function, 96% were free of cardiac symptoms, 80% were not receiving long-term
medical therapy, and 4% had an implantable cardioverter-defibrillator [131]. Another study including
222 paediatric patients with DCM due to myocarditis revealed a five-year rate of freedom from
transplantation of 81% and an estimated survival of 92% at one year and 90% at two and five years [119].
In an apparently paradoxical way, patients with fulminant myocarditis have a more favourable
long-term survival than patients with acute myocarditis [61]. The initial clinical presentation of
abrupt-onset haemodynamic instability experienced by these patients requires an aggressive intensive
care management, which probably accounts for the better prognosis [4,61]. According to a Paediatric
Cardiomyopathy Registry study, most patients experience normalization of ventricular size and
systolic function within several months and it is more likely to occur in patients with a normal left
ventricular diastolic diameter or with a greater left ventricular posterior wall thickness [132].
9. New Perspectives
Throughout the past few decades, our understanding of the molecular basis of myocarditis has
grown, which has allowed the development of many diagnostic and therapeutic innovations [90,118,132].
New molecular technologies have recently been used to characterize upregulations in micro-RNA
profiles during the pathological progression of myocarditis [76]. Additionally, prevention of
remodelling of the myocardium by matrix metalloproteinases and identification of potent novel
antivirals and biological medications seem to be appealing treatment concepts and are currently on
the radar of some recent studies [118]. These promising avenues may lead to future development of
interesting and accurate targets for the diagnosis and treatment of myocarditis in paediatric patients.
10. Conclusions
Myocarditis is a potentially life-threatening disease often clinically disguised as a benign one.
Its tendency to occur in young patients makes it one of the most frequent causes of DCM in this age
group. The amount of research made in experimental animal models in the last few decades has
allowed a better understanding of this disease, particularly its triphasic nature. However, assessing an
unambiguous prompt diagnosis of myocarditis and correctly staging it probably remains the hardest
challenge for clinicians, as this information is useful to initiate a specific treatment and improve the
outcome. Therefore, further clinical trials are needed in a quest for novel efficient diagnosis and
treatment strategies, which could eventually lead to a reduction in paediatric morbidity and mortality.
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